Are Analysts Bullish about Kite Pharma Inc (NASDAQ:KITE) after last week?

Paterniano Del Favero
Agosto 10, 2017

The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Vetr's target price suggests a potential downside of 2.76% from the company's previous close.

A number of other brokerages have also recently commented on KITE.

A number of hedge funds and other institutional investors have recently bought and sold shares of KITE. It dropped, as 34 investors sold Kite Pharma Inc shares while 43 reduced holdings. BlackRock Inc. now owns 3,621,971 shares of the biopharmaceutical company's stock valued at $284,287,000 after buying an additional 3,618,566 shares during the period.

As of the end of the quarter Pacer Advisors, Inc. had acquired a total of 1,083 shares growing its stake by 22.7%. Baillie Gifford & Co. acquired a new stake in Kite Pharma during the first quarter valued at about $201,000. Turner Investments LLC acquired a new stake in Kite Pharma during the first quarter valued at approximately $235,000.

On August 30 analysts at BTIG Research starting coverage on KITE setting a rating of "Neutral". Following the sale, the director now owns 155,017 shares in the company, valued at approximately $13,095,836.16. Hudson Bay Capital Management L P has 0.12% invested in Kite Pharma Inc (NASDAQ:KITE) for 122,626 shares.

Shares of Kite Pharma (NASDAQ:KITE) traded down 0.13% during trading on Wednesday, reaching $119.97. The stock is trading at $120.13 just above $103.84, the 50 day moving average and a bit higher than the 200 day moving average of $79.27. The company's market capitalization is $5.84 billion.

Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings data on Monday, May 8th.

Jpmorgan Chase & Co reports that it bought 413,513 shares in quarter ending 06/30/2017 increasing its holdings in Kite Pharma, 1,763.6%. The firm had revenue of $10.10 million during the quarter, compared to the consensus estimate of $9.59 million. Kite Pharma had a negative net margin of 1,166.54% and a negative return on equity of 55.80%. The company's revenue was up 92.2% compared to the same quarter a year ago.

They expect $-1.97 EPS, down 33.5% or $0.66 from last year's $-1.31 per share. Equities research analysts anticipate that Kite Pharma, Inc. will post ($8.45) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives.

Shares of Kite Pharma, Inc. The EVP now owns $5,437,952 of the stock as reported to the SEC. If you are viewing this piece on another website, it was stolen and reposted in violation of United States and worldwide trademark and copyright legislation.

According to the the latest analyst ratings which have been released, 4 brokers have issued a rating of "buy", 3 brokers "outperform", 5 brokers "hold", 0 brokers "underperform" and 1 brokers "sell". UBS AG cut Kite Pharma from an "outperform" rating to a "market perform" rating in a research note on Monday, May 8th.

03/13/2017 - Kite Pharma, Inc. was downgraded to "hold" by analysts at Standpoint Research. FBR & Co reaffirmed a "buy" rating on shares of Kite Pharma in a research report on Tuesday, May 30th.

On July 13 the company was rated "Hold" in a report from Maxim Group which is down from the previous "Buy" rating. The company has a consensus rating of "Buy" and an average price target of $87.66.

In related news, COO Cynthia M. Butitta sold 10,000 shares of Kite Pharma stock in a transaction that occurred on Friday, June 9th. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company's stock valued at $64,354,000 after buying an additional 575,178 shares in the last quarter. Also, EVP Timothy L. Moore sold 12,000 shares of the company's stock in a transaction on Tuesday, August 1st.

Cynthia M. Butitta, Chief Operating Officer sold $1,543,350 worth of shares at an average price of $102.89 on Monday the 10th.

On 6/26/2017 Owen N Witte, Director, sold 25,000 with an average share price of $100.30 per share and the total transaction amounting to $2,507,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 165,099 shares of company stock valued at $16,244,448.

And it remains to be seen which target price KITE can achieve without sacrificing much as the company is holding a 106.23% gain for the past twelve months.

Altre relazioni OverNewsmagazine

Discuti questo articolo